OncoMatch/Clinical Trials/NCT06815029
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Is NCT06815029 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Chimeric Antigen Receptor T-Cell Therapy for recurrent astrocytoma, idh-mutant, grade 3.
Treatment: Chimeric Antigen Receptor T-Cell Therapy — This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. When the cells are taken from the patient's own blood, it is known as autologous. Then the gene for special receptors that bind to a certain proteins on the patient's tumor cells are added to the T cells in the laboratory. The special receptors are called CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving TGFβR2KO/IL13Rα2 CAR T cells may be safe, tolerable, and/or effective in treating patients with recurrent or progressive glioblastoma or grade 3 or 4 IDH-mutant astrocytoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 mutation
Required: IL13RA2 overexpression (h-score ≥ 80)
Disease stage
Required: Stage GRADE 3, GRADE 4 (WHO CNS)
grade 3 or 4 IDH-mutant astrocytoma or glioblastoma; radiographic evidence of recurrence/progression of measurable disease
Prior therapy
Must have received: radiation therapy — front-line
radiographic evidence of recurrence/progression of measurable disease after standard therapy, and ≥ 12 weeks after completion of front-line radiation therapy
Cannot have received: bevacizumab (bevacizumab)
participants who require active bevacizumab therapy at the time of enrollment are excluded
Lab requirements
Blood counts
WBC > 2000/dl (or ANC ≥ 1,000/mm^3); Platelets ≥ 75,000/mm^3; Hemoglobin ≥ 8g/dl
Kidney function
Serum creatinine ≤ 1.6 mg/dL
Liver function
Total bilirubin ≤ 1.5 x ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN
WBC > 2000/dl (or ANC ≥ 1,000/mm^3); Platelets ≥ 75,000/mm^3; Hemoglobin ≥ 8g/dl; Total bilirubin ≤ 1.5 x ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN; Serum creatinine ≤ 1.6 mg/dL; O2 saturation ≥ 95% on room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06815029 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bevacizumab disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 mutation is a required biomarker for enrollment.
Does this trial require IL13RA2?
Yes, IL13RA2 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage GRADE 3 or GRADE 4 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages